<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35015904</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-3083</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the European Academy of Dermatology and Venereology : JEADV</Title>
          <ISOAbbreviation>J Eur Acad Dermatol Venereol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pityriasis lichenoides et varioliformis acuta following COVID-19 mRNA vaccination.</ArticleTitle>
        <Pagination>
          <StartPage>e327</StartPage>
          <EndPage>e328</EndPage>
          <MedlinePgn>e327-e328</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jdv.17912</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Palmén</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Dermatology, Turku University Hospital and University of Turku, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lepistö</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Pathology, Turku University Hospital and University of Turku, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Talve</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Pathology, Turku University Hospital and University of Turku, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hieta</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0001-6449-3076</Identifier>
            <AffiliationInfo>
              <Affiliation>Departments of Dermatology, Turku University Hospital and University of Turku, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Eur Acad Dermatol Venereol</MedlineTA>
        <NlmUniqueID>9216037</NlmUniqueID>
        <ISSNLinking>0926-9959</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017514" MajorTopicYN="Y">Pityriasis Lichenoides</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
          <Hour>17</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35015904</ArticleId>
        <ArticleId IdType="doi">10.1111/jdv.17912</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. Am J Clin Dermatol 2007; 8: 29-36.</Citation>
        </Reference>
        <Reference>
          <Citation>Jung F, Sibbald C, Bohdanowicz M, Ingram JR, Piguet V. Systematic review of the efficacies and adverse effects of treatments for pityriasis lichenoides. Br J Dermatol 2020; 183: 1026-1032.</Citation>
        </Reference>
        <Reference>
          <Citation>McMahon DE, Amerson E, Rosenbach M et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46-55.</Citation>
        </Reference>
        <Reference>
          <Citation>Castro BA, Pereira JM, Meyer RL, Trindade FM, Pedrosa MS, Piancastelli AC. Pityriasis lichenoides et varioliformis acuta after influenza vaccine. An Bras Dermatol 2015; 90: 181-184.</Citation>
        </Reference>
        <Reference>
          <Citation>Jastrząb BA, Stefaniak AA, Hryncewicz-Gwóźdź A, Nockowski P, Szepietowski JC. Pityriasis lichenoides et varioliformis acuta triggered by human papillomavirus vaccine: a case report and literature review. Acta Derm Venereol 2021; 101: adv00552.</Citation>
        </Reference>
        <Reference>
          <Citation>Gianotti R, Restano L, Cutrone M et al. Papulo-purpuric dermatitis of childhood: a distinct PLEVA-like eruption associated to SARS-CoV-2 infection. Clinical, histopathological and immunohistochemical study of 10 cases. Pediatr Dermatol 2021; 38: 1185-1190.</Citation>
        </Reference>
        <Reference>
          <Citation>Durusu IN, Gurel G, Tokyol C. A case of pityriasis lichenoides chronica in a patient with COVID-19 infection. Actas Dermosifiliogr 2021. https://doi.org/10.1016/j.ad.2021.09.002</Citation>
        </Reference>
        <Reference>
          <Citation>Sechi A, Pierobon E, Pezzolo E et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clin Exp Dermatol 2021. https://doi.org/10.1111/ced.14970</Citation>
        </Reference>
        <Reference>
          <Citation>Sernicola A, Dybala A, Gomes V et al. Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption. J Eur Acad Dermatol Venereol 2022; 36: e172-e174.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
